Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study developed a nanostructured lipid carrier for 17-α-estradiol that showed stable physicochemical properties and improved targeting to hair follicles in alopecia treatment.

This review discusses recent advancements in female contraception and covers topics like adapted regimens, non-invasive sterilization, and the promise of new methods, but it reports no new clinical findings.

This review discusses the increased risk of venous thromboembolism associated with combined hormonal contraceptives, particularly noting higher risks with certain progestins like desogestrel, gestodene, and cyproterone acetate, but reports no new clinical findings.

This study found that the combination of cyproterone acetate and ethinyl estradiol improved hirsutism and acne in women, with SH 8.1041 showing significant results and both treatments being generally well-tolerated.

This study observed that new trienone compounds consistently showed higher 5alpha-reductase inhibitory activity compared to corresponding dienones across various biological models.

This study found that cyproterone acetate with ethynyl estradiol improved acne and seborrhea within 3–6 months in women, but had less satisfactory results for alopecia and hirsutism.

Hormonal contraceptives and related compounds can increase health risks like thrombosis and affect sexual function.

The birth control pill containing ethinylestradiol and chlormadinone may help treat acne and other skin and hair conditions related to hormones.

Two women had skin reactions from a hair loss treatment and got better after stopping use.

This study observed a strong overall reduction in the use of CPA/EE in the Netherlands, despite similar proportions of users with acne or other hyperandrogenic conditions before and after the referral procedure.

This study found that a single 2 ml injection of TEEV every 4 weeks offers similar beneficial effects with fewer side effects compared to injecting the same dose every 2 weeks in postmenopausal women.

This study found that a combination of cyproterone acetate and ethinyl estradiol over one year did not affect glucose tolerance but increased total cholesterol, HDL cholesterol, and triglycerides in patients with moderate hyperandrogenism.

This study reported that the combination of EE-CPA and raloxifene effectively manages PCOS-related infertility, enhancing pregnancy outcomes through improvements in metabolism, sex hormones, ovarian function, and endometrial receptivity, without significantly increasing adverse effects.

This review covers the use of combined oral contraceptives, particularly drospirenone, for managing polycystic ovary syndrome and discusses related metabolic controversies without reporting new clinical results.

Both LNG-IUD and systemic progestins are effective for fertility-sparing treatment, but close monitoring is needed due to recurrence risk.

This review found that adding cyproterone acetate to estradiol showed a subjective improvement in hirsutism versus placebo, but comparisons with other therapies revealed no clinical differences.

In this study, Diane was reported to effectively treat acne, seborrhoea, androgenic alopecia, and mild hirsutism in hirsute women, with its effectiveness influenced by the severity and duration of the condition.

This source highlights the role of progestin in contraception, noting that while different types have varying progesteronic potential and effects, they share similar contraceptive mechanisms, allowing tailored use based on patient conditions.

This review suggests that estroprogestins with anti-androgenic progestins, like cyproterone acetate and drospirenone, may effectively manage androgen excess in PCOS women, considering individual patient profiles.

This study found that most UK women prescribed cyproterone acetate/ethinylestradiol before and after 2013 had conditions aligning with approved indications and prior acne treatment.

This study concluded that combining letrozole with cabergoline improved ovulation and clinical pregnancy rates in patients with polycystic ovarian syndrome and hyperprolactinemia compared to letrozole alone.

This study reviewed various dermatological conditions associated with oral contraceptive use, highlighting increased pigmentation, decreased sebum production, and changes in hair growth, among other effects.

This study found that compliance rates for oral contraceptives are low and similar to those for other medical treatments, indicating a need for alternatives that require less daily adherence.

This study found that EE/CPA and EE/DES were both effective in reducing hirsutism in patients with PCOS, with no additional benefit from adding low-dose metformin.

In this study, hirsute women treated with cyproterone acetate and ethinyloestradiol experienced significant reductions in sebum secretion and hair growth after several months.

This case report describes a woman who developed toxic epidermal necrolysis, potentially linked to an etonogestrel contraceptive implant, suggesting the need for further research into such adverse reactions.

This study found that the combined oral contraceptive containing ethinyl estradiol and chlormadinone acetate was effective in reducing moderate papulopustular acne and other androgen-related skin disorders compared to placebo.

This review highlights that Cyproterone acetate combined with ethinylestradiol is highly effective for treating severe acne and hirsutism in women with hyperandrogenism, and it also provides benefits for cycle control and mood improvement, according to the analysis of 78 studies.